Latest News

FDA approves NVX-CoV2705 COVID-19 vaccine | Image credit: Contemporary Pediatrics
FDA approves NVX-CoV2705 COVID-19 vaccine

May 19th 2025

NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes.

RSV data highlight age- and condition-specific risks for severe disease in children | Image Credit: © bankrx - © bankrx  - stock.adobe.com.
Age, condition-specific risks for severe RSV disease in children

May 17th 2025

USPSTF: Syphilis screening during pregnancy has 'substantial' net benefit | Image Credit: © Kostia - © Kostia - stock.adobe.com.
USPSTF: Syphilis screening during pregnancy has 'substantial' net benefit

May 14th 2025

Infant RSV hospitalization rates 28%, 43% lower this season vs pre-COVID seasons | Image Credit: © MargJohnsonVA - © MargJohnsonVA - stock.adobe.com.
Infant RSV hospitalization rates 28%, 43% lower this season vs pre-COVID seasons

May 9th 2025

RSV prophylaxis: Palivizumab, nirsevimab, and more | Image Credit: © John Doe - © John Doe - stock.adobe.com.
RSV prophylaxis: Palivizumab, nirsevimab, and more

May 6th 2025

Video Interviews
Podcasts
children on tablet
COVID-19 vaccine

More News

© 2025 MJH Life Sciences

All rights reserved.